Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Roscilli, Giuseppe ^a   Cappelletti, Manuela ^a   De Vitis, Claudia ^b   Ciliberto, Gennaro ^c   Di Napoli, Arianna ^d   Ruco, Luigi ^d   Mancini, Rita ^b,d   Aurisicchio, Luigi ^a,e  

^a University La Sapienza ^*

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Grande Ospedale Metropolitano   (Italy)

Author keywords

Immune response; MMP11; Tumor stroma

Indexed keywords

AUTOANTIBODY; MMP11 AUTOANTIBODY; STROMELYSIN 3; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 11; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84896739631     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-54     Document Type: Article

References (19)

1. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013, 228(Suppl. 8):1651-1657.
2. Fukuda K, Kobayashi A, Watabe K. The role of tumor-associated macrophage in tumor progression. Front Biosci (Schol Ed) 2012, 4:787-798.
3. Becker JC, Andersen MH, Schrama D, Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 2013, 62(Suppl. 7):1137-1148.
4. Zhang B. Targeting the Stroma by T cells to limit tumor growth. Cancer Res 2008, 68:9570-9573. 10.1158/0008-5472.CAN-08-2414, 19047130.
5. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008, 57:1-17.
6. Vihinen P, Ala-Aho R, Kähäri VM. Diagnostic and prognostic role of matrix metalloproteases in cancer. Expert Opin Med Diagn 2008, 2(Suppl. 9):1025-1039.
7. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013, 34(Suppl. 4):2041-2051.
8. Yi T, Wei YQ, Tian L, Zhao X, Li J, Deng HX, Wen YJ, Zou CH, Tan GH, Kan B, Su JM, Jiang Y, Mao YQ, Chen P, Wang YS. Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. Cancer Gene Ther 2007, 14:158-164. 10.1038/sj.cgt.7700994, 17124509.
9. Yokoyama Y, Grunebach F, Schmidt SM, Heine A, Hantschel M, Stevanovic S, Rammensee HG, Brossart P. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res 2008, 14:5503-5511. 10.1158/1078-0432.CCR-07-4041, 18765542.
10. Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N, Aurisicchio L. MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res 2009, 15(12):4104-4113. 10.1158/1078-0432.CCR-08-3226, 19509157.
11. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004, 10:2832-2845. 10.1158/1078-0432.CCR-1157-03, 15102692.
12. Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Hofler H. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations. Diagn Mol Pathol 1996, 5:284-290. 10.1097/00019606-199612000-00010, 8955621.
13. Cheng CW, Yu JC, Wang HW, Huang CS, Shieh JC, Fu YP, Chang CW, Wu PE, Shen CY. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta 2010, 411(3-4):234-241.
14. Nonsrijun N, Mitchai J, Brown K, Leksomboon R, Tuamsuk P. Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival. Asian Pacific J Cancer Prev 2013, 14(Suppl. 5):3331-3335.
15. Anne MD, Ernesto C. Dual regulation of stromelysin-3 by fibroblast growth factor-2 in murine osteoblasts. J Biol Chem 1998, 273:16595-16600. 10.1074/jbc.273.26.16595, 9632732.
16. Deng H, Guo RF, Li WM, Zhao M, Lu YY. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun 2005, 326:274-281. 10.1016/j.bbrc.2004.11.027, 15582574.
17. Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 2005, 65(Suppl. 2):650-656.
18. Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, Li CI, Prentice R, Hanash SM, Disis ML. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 2012, 5(Suppl. 8):1036-1043. 3790582, 22715141.
19. Dai L, Lei N, Liu M, Zhang JY. Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). Exp Hematol Oncol 2013, 2(Suppl. 1):15. 3665485, 23687996.